Visit Asuragen at the AACR Annual Meeting Booth #2738

The Asuragen Oncology portfolio helps drive the understanding of cancer at a molecular level, advancing our knowledge of disease etiology and progression and contributes to the evolution of precision medicine.

Coming soon to the QuantideX® NGS family

Coming soon to the QuantideX® NGS family

QuantideX® NGS RNA Lung Cancer Kit*


The assay analyzes important NSCLC events, including:

  • RNA fusions (110)
  • MET exon 14 skipping
  • 3′-5′ imbalances
  • Gene expression

Visit us at Booth #2738 for details on our Early Access Program.

QuantideX® NGS Pan Cancer Kit*quantidex_ngs_pan_cancer_kit_logo_2c_RGB-300x86


  • Multiplexed profiling of the most clinically relevant* mutations in a wide range of human cancers with high performance in low quality/quantity samples
  • Designed & optimized for rapid deployment, regardless of NGS experience or knowledge-level
  • A comprehensive workflow, containing all elements for ready-to-go Illumina sequencing, including sample QC, library prep, clean up and quantification
  • Leverages Asuragen’s integrated analytics and reporting suite, QuantideX® NGS Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels

*For Research Use Only. Not for use in diagnostic procedures.

QuantideX® qPCR DNA QC Assay*quantidex_qpcr_dna_qc_assay_logo_2c_RGB-300x86


  • Measures the DNA that matters: PCR-amplifiable DNA
  • Provides actionable guidance that rescues low-quality DNA and helps assure the accuracy of next-generation sequencing calls
  • A 2-in-1 assay: Distinguishes low-quality, unamplifiable DNA from DNA with sample-derived PCR inhibition
  • Simple, high-throughput workflow using a convenient multiplexed design
  • Ideal for quantifying challenging sample types like FFPE and FNA

*For Research Use Only. Not for use in diagnostic procedures.


Poster #: 1389
Author: Gary Latham, PhD
Title/Synopsis: A unified and streamlined targeted sequencing system for the quantification of DNA mutations and RNA expression markers in lung cancer

This collaborative poster with MD Anderson Cancer Center demonstrates how QuantideX® NGS technology can be used to identify DNA mutations and indels, and RNA expression markers and translocations, from challenging NSCLC FFPE samples. We also describe feasibility for RT-PCR enrichment of DNA and RNA markers from a single input of total nucleic acid using a highly streamlined workflow.
Poster Presentation: April 18, 2016   8:00 AM – 12:00 PM

One Partner From Clinical Concept to Product Commercialization

Asuragen has a proven track record of extracting valuable information from challenging samples. Our unique translational diagnostics model supports all phases of diagnostic development. From discovery through commercialization, we offer a full range of tailored custom and companion diagnostic solutions.

Our portfolio of enabling technologies coupled with our team of industry experts enables us to support upfront discovery activities, assay development, clinical testing, regulatory filing, cGMP manufacturing of diagnostic kits and product commercialization

One partner for translational research

  • Multiple platforms for biomarker discovery
  • Iterative, consultative bioinformatics
  • Off-the-shelf and customized solutions (NGS, PCR & Microarray)
  • Chemistry platforms delivering optimized workflows for challenging sample types

One partner for clinical trial testing

  • Highly-multiplexed assays developed with diagnostic-ready reagents
  • CAP-accredited CLIA laboratory
  • Analytical validation
  • Custom algorithm development

One partner for diagnostic test development

  • cGMP kit manufacturing under design control
  • Global commercialization
  • Regulatory expertise
  • Custom diagnostic reagents

Stop by Booth #2738 to learn more about our solutions and companion diagnostic partnerships.

Back To